Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05443126 · ClinicalTrials.gov registry record · Phase 1

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Ellipses Pharma.

Recruiting
Registry status
Phase 1
Development phase
265
Enrollment target
20
Study locations

NCT05443126 is a Phase 1 study of Advanced Solid Tumor and NSCLC that is actively recruiting participants, run by Ellipses Pharma. The registered enrollment target is 265 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05443126, a Phase 1 study of Advanced Solid Tumor and NSCLC, is actively recruiting participants, sponsored by Ellipses Pharma.

RECRUITING
Registry status
Phase 1
Development phase
265 participants
Enrollment target
20
Study locations

Study Summary

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)

Conditions Studied

Advanced Solid Tumor NSCLC

Interventions

  • DRUG EP0031

Study Locations (20)

California

  • David Geffen School of Medicine at UCLA - Los Angeles
  • Stanford University - Stanford

Illinois

  • RUSH University Medical Center - Chicago
  • Northwestern University - Evanston

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • NYU Langone Health - New York

Washington

  • Washington University - Seattle
  • Seattle Cancer Care / Fred Hutchinson Cancer Research Center - Seattle

District of Columbia

  • Georgetown University - Washington D.C.

Florida

  • Florida Cancer Specialist - Fort Myers

Kentucky

  • University of Kentucky - Lexington

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 265 participants
Start Date 2022-09-30
Est. Completion 2027-06
Phase Phase 1

Sponsor

Ellipses Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05443126

The ClinicalTrials.gov registry entry for NCT05443126 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (38% higher). The listed sponsor is Ellipses Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which EP0031 is the first listed.

NCT05443126 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT05443126 about?

NCT05443126 is a clinical study titled "A Study of EP0031 in Patients With Advanced RET-altered Malignancies". The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)

What is the current status of trial NCT05443126?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 265 participants. The study started on 2022-09-30. Estimated completion is 2027-06.

What conditions does trial NCT05443126 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC.

What interventions are being tested in trial NCT05443126?

The interventions under investigation include: EP0031 (DRUG).

Who is sponsoring clinical trial NCT05443126?

This trial is sponsored by Ellipses Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05443126 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

NSCLC

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.